tbuckley/cabot-search huggingface dataset:
Human papillomavirus (HPV) in young patients with head and neck squamous cell carcinoma.
Authors: Teerapat Ungtrakul, Somboon Keelawat, Chanida Vinayanuwattikun, Virote Sriuranpong
Journal: Journal of Clinical Oncology (2013)

e17004 Background: HPV-associated head and neck squamous cell carcinoma (HNSCC) seems to increase during the last decades and has been commonly described to associate with younger patients. However the true prevalence of HPV in this specific population remains unclear. Methods: We collected archival 56 paraffin-embedded tumor tissue samples from HNSCC patients diagnosed and treated at King Chulalongkorn Memorial Hospital between 2000 and 2010. The major inclusion criterion was the age at diagnosis less than 45 year-old. HPV status was determined by HPV polymerase chain reaction (PCR) with degenerated primer covered over 37 HPV serotypes including high-risk HPV6, 11, 16, 18, 31 and 33. Additional immunohistochemical stain (IHC) of p16 was performed. The clinicopathological correlations with HPV status were analyzed. Results: Fourteen (25%) of the 56 HNSCC samples exhibited HPV DNA by PCR. Among cancer sites, 7 of 23 (30%) oral cavity, 3 of 11 (27%) oropharynx, and 4 of 22 (18%) hypopharynx and larynx primary organs displayed HPV DNA in tumor tissues. There was no major difference in the demographic data, tumor characteristics and treatment modalities between HPV DNA-negative and HPV DNA-positive samples. HPV DNA-positive tumors tended to have a better 2-year overall survival when compared with HPV DNA-negative tumors (66 and 40 percent, respectively) (p=0.10). After adjusted for independent prognostic variables of cigarette smoking, alcohol consumption, site of primary tumor and nodal status, only HPV DNA status was a predictor for a better survival (HR 0.16; 95%CI, 0.01-0.66). Additional IHC for p16 expression revealed 8 of 48 (16%) of p16 overexpression with twenty-two percent concordant rate with HPV PCR. Conclusions: Though HPV genome was moderately found in our young HNSCC patients, HPV DNA was not associated with a significant better survival in the primary analysis. Nevertheless, multivariate analysis adjusting for prognostic variables demonstrated a significant better prognosis in HPV DNA-positive tumors in this subset of HNSCC. Low concordant rate between HPV DNA and p16 overexpression in these young populations may caution the use of p16 overexpression as a surrogate marker of HPV.
DRUG-COATED BALLOONS IN THE TREATMENT OF DE-NOVO CORONARY ARTERY DISEASE: A NETWORK META-ANALYSIS OF ALL RANDOMIZED CONTROLLED TRIALS
Authors: Babikir Kheiri, Timothy Simpson, Mohammed Osman, Kris Kumar, Qais Radaideh, Harsh Golwala, Punag Divanji, Joaquin Cigarroa, Firas Zahr
Journal: Journal of the American College of Cardiology (2020)
LATE GADOLINIUM ENHANCEMENT IS ASSOCIATED WITH ADVANCED BIVENTRICULAR DYSFUNCTION IN PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
Authors: Shahd Mohamed, Miranda Kunz, Susan Casey, Katelyn Storey, William T. Katsiyiannis, Raed Abdelhadi, Allison Berg, Christian Schmidt, Jay Sengupta
Journal: Journal of the American College of Cardiology (2020)
Effect of dormant cancer cells on angiogenesis after resisting chemotherapy.
Authors: Sumiyuki Mii, Yasunori Tome, Yukihiko Hiroshima, Fuminari Uehara, Shinji Miwa, Toshiyoshi Fujiwara, Robert M. Hoffman, Shuya Yano
Journal: Journal of Clinical Oncology (2013)

e13577 Background: Dormant cancer cells are a significant problem in clinical cancer as they are usually chemoresistant and can give rise to recurrence years after treatment. Methods: Dormant cancer cells were identified with a fluorescence ubiquitination cell cycle indicator (FUCCI) and confocal microscopy. FUCCI-expressing xenografts were established from MKN45 gastric cancer cells. Results: Within 7 days after implantation in nude mice, FUCCI-expressing tumors contained a mixture of cancer cells in G 0 /G 1 and S/G 2 /M phases. Cancer cells in G 0 /G 1 phase survived and become dormant after treatment with cytotoxic agents. As the tumors grew, proliferating cells were only found at the surface. Chemotherapy killed only the proliferating cancer cells at the surface and had little effect on the majority of dormant cancer cells in the tumor center. Furthermore, we investigated tumor chemoresistance using nestin-driven green fluorescent protein (GFP) transgenic mice that have GFP-expressing nascent tumor vessels. Chemotherapy-treated tumors had much more and deeper tumor vessels than control tumors. Conclusions: These results suggest that dormant cancer cells may protect themselves by inducing angiogenesis.
Association Between American Board of Surgery Initial Certification and Risk of Receiving Severe Disciplinary Actions Against Medical Licenses
Authors: Jason P. Kopp, Beatriz Ibáñez, Andrew T. Jones, Xiaomei Pei, Aaron Young, Katie Arnhart, Anne G. Rizzo, Jo Buyske
Journal: JAMA Surgery (2020)

<h3>Importance</h3> Board certification is used as a marker of surgeon quality and professionalism. Although some research has linked certification in surgery to outcomes, more research is needed. <h3>Objective</h3> To measure associations between surgeons obtaining American Board of Surgery (ABS) certification and examination performance with receiving future severe disciplinary actions against their medical licenses. <h3>Design, Setting, and Participants</h3> Retrospective analysis of severe license action rates for surgeons who attempted ABS certification based on certification status and examination performance. Surgeons who attempted to become certified were classified as certified or failing to obtain certification. Additionally, groups were further categorized based on whether the surgeon had to repeat examinations and whether they ultimately passed. The study included surgeons who initially attempted certification between 1976 and 2017 (n = 44 290). Severe license actions from 1976 to 2018 were obtained from the Federation of State Medical Boards, and certification data were obtained from the ABS database. Data were analyzed between 1978 and 2008. <h3>Main Outcomes and Measures</h3> Severe license action rates were analyzed across certified surgeons and those failing to obtain certification, as well as across examination performance groups. <h3>Results</h3> The final dataset included 36 197 men (81.7%) and 8093 women (18.3%). The incidence of severe license actions was significantly greater for surgeons who attempted and failed to obtain certification (incidence rate per 1000 person-years = 2.49; 95% CI, 2.13-2.85) than surgeons who were certified (incidence rate per 1000 person years = 0.77; 95% CI, 0.71-0.83). Adjusting for sex and international medical graduate status, the risk of receiving a severe license action across time was also significantly greater for surgeons who failed to obtain certification. Surgeons who progressed further in the certification examination sequence and had fewer repeated examinations had a lower incidence and less risk over time of receiving severe license actions. <h3>Conclusions and Relevance</h3> Obtaining board certification was associated with a lower rate of receiving severe license actions from a state medical board. Passing examinations in the certification examination process on the first attempt was also associated with lower severe license action rates. This study provides supporting evidence that board certification is 1 marker of surgeon quality and professionalism.
HEPARIN ASSOCIATED WITH PRE-TREATMENT WITH DUAL ANTIPLATELET THERAPY IMPROVES CORONARY REPERFUSION BEFORE PRIMARY ANGIOPLASTY IN PATIENTS WITH STEMI
Authors: Roberta Montisci, Piero Caddeo, Michela Congia, Roberta Scotto, Maria Francesca Marchetti, Cristina Cacace, Mattia Biddau, Enrica Garau, Luigi Meloni
Journal: Journal of the American College of Cardiology (2020)
Cardiovascular Imaging Through the Prism of Modern Metrics
Authors: Andrew D. Choi, Jeffrey B. Geske, Juan C. Lopez-Mattei, Purvi Parwani, Dee Dee Wang, David E. Winchester, Partho P. Sengupta, William A. Zoghbi, Leslee J. Shaw, Y.S. Chandrashekhar, Ron Blankstein
Journal: JACC. Cardiovascular imaging (2020)
DIRECT ORAL ANTICOAGULANTS STRATEGIES IN ACUTE CORONARY SYNDROMES: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Authors: Leonardo Mees Knijnik, Marcelo Fernandes, Manuel Rivera Maza, Raul Montanez-Valverde, Rhanderson Cardoso, Amanda Fernandes, Gilson Fernandes, Mauricio G. Cohen
Journal: Journal of the American College of Cardiology (2020)
CLINICAL PROFILE AND MANAGEMENT OF PATIENTS WITH ACUTE PULMONARY THROMBOEMBOLISM: A LARGE EXPERIENCE FROM A QUATERNARY CARE CENTRE FROM SOUTHERN INDIA
Authors: Aditya Vikram Ruia, Muralidharan Ramamurthy, Nagendra Senguttuvan, Vinodkumar Balakrishnan, Mano Vikash Vallivedu, Bhavidra Ramkumar, Balakrishna Malepati, Sadagopan Thanikachalam, Ramesh Sankaran, Manokar Panchanatham, Jayanty Murthy, Shanmugasundaram Sadhanandham, Jayanty Balasubramaniyam
Journal: Journal of the American College of Cardiology (2020)
Resource-rationality as a normative standard of human rationality
Authors: Matteo Colombo
Journal: Behavioral and Brain Sciences (2020)

Abstract Lieder and Griffiths introduce resource-rational analysis as a methodological device for the empirical study of the mind. But they also suggest resource-rationality serves as a normative standard to reassess the limits and scope of human rationality. Although the methodological status of resource-rational analysis is convincing, its normative status is not.
Inhibition of gamma-secretase activity in combination with paclitaxel to reduce platinum-resistant ovarian tumor growth.
Authors: Jolijn W Groeneweg, Celeste M DiGloria, Whitfield Board Growdon, Sriram Sathyanarayanan, Rosemary Foster, Bo R Rueda
Journal: Journal of Clinical Oncology (2013)

5578 Background: Ovarian cancer (OvCa) is the most lethal gynecologic malignancy in the United States. Chemotherapy is effective but seldom curative, mainly due to the development of chemoresistant recurrent disease. Our current research investigates the efficacy of inhibiting the Notch pathway with a gamma-secretase inhibitor (GSI), MRK-003, in an OvCa xenograft model as a single agent therapy and in combination with standard chemotherapy. Methods: Mice bearing xenografts derived from clinically platinum sensitive human ovarian serous carcinomas were treated with GSI or vehicle, or with either vehicle, GSI alone, paclitaxel and carboplatinum (T/C) alone, or the combination of GSI and T/C. In addition, mice bearing xenografts derived from patients with clinically platinum resistant disease were given GSI with or without paclitaxel. Gene transcript levels of several factors in the Notch pathway were analyzed using RT-PCR. Notch1 and Notch3 protein levels were evaluated by western blotting. The Wilcoxon rank-sum test was used to assess significance between the different treatment groups. Results: Expression of Notch1 and Notch3 was highly variable across all analyzed OvCa samples. Treatment with GSI alone significantly decreased tumor growth in 3 of 4 platinum sensitive ovarian tumors (all p &lt; 0.05), as well as in 1 of 3 platinum resistant tumors (p = 0.04). Furthermore, the combination of GSI and paclitaxel was significantly more effective than GSI alone and paclitaxel alone in all platinum resistant ovarian tumors (all p &lt; 0.05). The addition of GSI did not alter the effect of T/C in platinum sensitive tumors. Although the response of each tumor to GSI did not correlate with its endogenous level of Notch expression, 2 of the 3 tumors resistant to paclitaxel but sensitive to the combination of GSI and paclitaxel showed elevated Notch activity by RT-PCR. Conclusions: Inhibition of the Notch signaling cascade with a gamma-secretase inhibitor reduces tumor growth in vivo, most notably in combination with paclitaxel in a platinum resistant setting. These promising findings underscore the need for further investigation of the preclinical and clinical effectiveness of Notch inhibitors in OvCa.
PET/CT can direct diagnostic and therapeutic decisions in pancreatic lesions
Authors: V. Casneuf, L. Delrue, M. Kelles, F. Berrevoet, P. Duyck, B. De Hemptinne, N. Van Damme, E. Monsaert, M. Peeters
Journal: Journal of Clinical Oncology (2006)

14048 Background: This study aimed to determine the role of PET/CT in differentiating pancreatic lesions and changing therapeutic approach. Methods: A retrospective analysis of prospectively collected data of 33 PET/CT scans (Philips, Cleveland, USA) was performed. Scans were made between October 2004 and July 2005 for differentiating primary or recurrent pancreatic disease found on CT, MRI or/and EUS. All PET/CT scans were assessed by a radiologist in co-operation with a nuclearist. Pancreatic lesions were interpreted based on visual assessment and by use of a semi-quantitative evaluation (SUV). These results were correlated with pathological diagnoses or clinical follow-up, dividing patients into 2 groups: ‘positive’ (malignant) versus ‘negative’ (benign disease/no lesion). In each patient therapeutic change after PET/CT was assessed. Results: The patient group consisted of 33 consecutive patients, of whom 14 were female. Median age was 61 years (range 33–76 years). SUV values in malignant lesions were significantly higher than those found in benign lesions [5.77 (95%CI 4.08–7.46) versus 1.76 (95%CI 0.79–2.7), P&lt;0.01]. Eleven patients with benign disease or no lesion, had a negative PET/CT. Twenty-two patients had malignant disease of the pancreas. Twenty of 22 patients had a positive PET/CT. Sensitivity and specificity of PET/CT for diagnosing benign or malignant disease visually was 90.9% and 100% respectively. In the benign/no lesion group, a change in therapeutic approach was noted for 9/11 patients (81,8%): no surgery (n=6), no chemotherapy (recurrence excluded, n=3). No change was noted in 2/11 patients (18,2%): no differentiation pancreatitis/tumor. In the malignant group, a change in therapeutic approach was noted for 14/22 patients (63,6%): recurrence confirmed (n=8), up-staged (n=5), down-staged (n=1). No change was seen in 8/22 patients (36,4%): incorrectly sent to surgery (n=4), no differentiation pancreatitis/tumor (n=2), recurrence missed (n=1), false positive diagnosis of liver metastasis (n=1). Conclusions: PET/CT has 90.9% sensitivity and 100% specificity for diagnosing benign or malignant disease visually. PET/CT is a useful tool for directing therapeutic strategy. Overall, therapeutic approach was changed in 23/33 (69,7%) of patients. No significant financial relationships to disclose.
Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function
Authors: Yasuhiro Nagate, Sachiko Ezoe, Jiro Fujita, Daisuke Okuzaki, Daisuke Motooka, Tomohiko Ishibashi, Michiko Ichii, Akira Tanimura, Masako Kurashige, Eiichi Morii, Takuya Fukushima, Youko Suehiro, Takafumi Yokota, Hirohiko Shibayama, Kenji Oritani, Yuzuru Kanakura
Journal: Leukemia (2020)

Abstract Adult T-cell leukemia/lymphoma (ATLL) patients have an extremely poor prognosis, partly due to their immunosuppressive state. The majority of ATLL patients have leukemic cells with phenotype similar to Tregs, prompting suggestions that ATLL cells themselves have immunosuppressive functions. In this study, we detected CD39 expression on ATLL cells, particularly frequent on aggressive subtypes. CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs’ immunosuppression. In vitro culture, both CD39 + ATLL cells and normal Tregs converted rapidly extracellular ATP to AMP, which was disturbed by CD39 inhibitors, and was negated in the CD39 knockout MJ cell line. The proliferation of cocultured CD4 + /CD8 + normal T cells was suppressed by CD39 + MJ cells, but not by CD39 knockout MJ cells. Supplemented ATP was exhausted by an EG7-OVA T-cell line with stable CD39 induction, but not by mock. When these cell lines were subcutaneously transplanted into murine flanks, Poly(I:C) peritoneal administration reduced tumor size to 1/3 in mock-transplanted tumors, but not in CD39 induced tumors. Overall, we found that ATLL cells express CD39 at a high rate, and our results suggest that this helps ATLL cells escape antitumor immunity through the extracellular ATPDase-Adenosine cascade. These findings will guide future clinical strategies for ATLL treatment.
AB0100 Systemic manifestation of behcet adamantiades syndrome
Authors: DV Mitrovic, LJ Pavlica, BC Glisic, MR Petronijevic, G Pavlovic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> After the disease was firstly described it was beleived that this syndrome consisted of three symptoms ? orogenital ulcerations and inflammatory disease of eyes. In last several decades numerous facts indicated that we have deall systemic vasculitis, that induced multiorgan manifestations. <h3>Objectives</h3> The aim of this study is: a) to analyse 64 patients and find the spectrum of systemic manifestations of the disease, b) to show therapeutic approach in acute phase of the disease. <h3>Methods</h3> All patients fulfilled diagnostic criteria for the diagnosis of Behcet-Adamantiades syndrome. <h3>Results</h3> Out of systemic manifestations the most common was the involvement of locomotoric system ? arthritis 38 (59%), arthralgiae 25 (39%), tendinitis 3 (4.7%), sacroiliitis 1 (1.6%) and afterwards the involvement of cardiovascular system ? thrombophlebitis 11 (17%), thrombosis v. cavae inferior 2 (3.1%), v. cavae superior 1 (1.6%), involvement of cardiac structures 4 (6.2%). Central nervous system was involved in ten patients: meningoencephalitis in 2 ? 3.1%, pyramidal and extrapyramidal syndrome in 1 ? 1.6%, thrombosis of venous sinuses 1 ? 1.6%. Involvement of cranial nerves was found in 3 (4.7%) patients and peripheral neuropathy of sensorial type in 4 (6.2%). Pulmonary vasculitis was confirmed in one patient ? 16 year old girl in the acute phase of the disease. Enterocolitis was developed in 5 (7.8%) and orchiepididimytis in 2 (3.1%). In the acute phase of the disease all patients were treated with glucocorticoids and in case of multisystemic manifestations firstly with ?pulse? dose of methylprednisolone three days and afterwards cyclophosphamide in ?pulse? doses one monthly during 6 months and it was administered every 3 months until one year. A total of 19 patients were treated with cyclosporin A. Colchicin was administered in acute phase of the disease in patients with ocular involvement. Antieggregation treatment (Aspirin) was also administered. <h3>Conclusion</h3> This paper confirms that Behcet-Adamantiades syndrome is not only three-symptom disease but also systemic generalised vasculitis. Multisystemic manifestations developed due to systemic vasculitis.
AN ACUTE AORTIC SYNDROME PRESENTING AS SEVERE SHOULDER PAIN
Authors: Hilda Mariana Gonzalez Bonilla, Nitheesha Ganta, Ahmad Awan, Jenna Aziz, Andre J. Duerinckx, Prafulla Mehrotra, Isaac Opoku-Asare, Shawn Sarin, Salim Aziz
Journal: Journal of the American College of Cardiology (2020)
Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS
Authors: Yibin Liu, Jingfei Cheng, Paulina Siejka-Zielińska, Carika Weldon, Hannah Roberts, Maria Lopopolo, Andrea Magri, Valentina D’Arienzo, James M. Harris, Jane A. McKeating, Chun-Xiao Song
Journal: Genome biology (2020)

Abstract We present long-read Tet-assisted pyridine borane sequencing (lrTAPS) for targeted base-resolution sequencing of DNA methylation and hydroxymethylation in regions up to 10 kb from nanogram-level input. Compatible with both Oxford Nanopore and PacBio Single-Molecule Real-Time (SMRT) sequencing, lrTAPS detects methylation with accuracy comparable to short-read Illumina sequencing but with long-range epigenetic phasing. We applied lrTAPS to sequence difficult-to-map regions in mouse embryonic stem cells and to identify distinct methylation events in the integrated hepatitis B virus genome.
ECHOCARDIOGRAPHIC AND CLINICAL VARIABLES ARE DIFFERENTIALLY PREDICTIVE OF HEART FAILURE HOSPITALIZATION IN HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION
Authors: Michael M. Hammond, Changyu Shen, Dhruv Kazi, Allan L. Klein, Marwa A. Sabe, A. Reshad Garan, Sherif F. Nagueh, Jordan B. Strom
Journal: Journal of the American College of Cardiology (2020)
Inadequate data availability on clinical trial accrual and its effect on progress in cancer research.
Authors: Aaron Philip Mitchell, Bradford Richard Hirsch, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2013)

e15572 Background: Participant accrual is a critical benchmark in clinical research, predicting study completion and reflecting the perceived value of the clinical question and study designed to answer it. Timely accrual data can be used prospectively to inform the design of new clinical trials. Accrual statistics are available within research networks, such as the cancer cooperative groups, but comprehensive data reflecting the overall portfolio of cancer clinical trials are lacking. As a demonstration case, we tested the availability of accrual data across all recent renal cell carcinoma (RCC) studies. Methods: The database for the Aggregate Analysis of ClinicalTrials.gov (CTG) summarizes all trials registered between 10/2007-9/2010. 137 RCC trials were included, of which 108 focused on pharmacologic therapy. Accrual data on these trials were gathered from CTG, online surveys sent to principle investigators, trial coordinators, and/or industry sponsors, review of resulting publications, and follow up phone calls to non-responders. Results: 20 of 76 (26%) trials listing a government, academic, or cooperative group (GAC) sponsor responded to the survey vs 0 of 32 (0%) of those listing only industry (I) sponsors. Across all methods, accrual data were collected for 43 trials (40%), including 28 of 76 (37%) GAC trials and 15 of 32 (47%) I trials. 87% of GAC trials which were ongoing (open, actively recruiting, or of unknown status) vs 75% of I trials. 10 of 108 trials (9%) were closed prematurely. Conclusions: Despite extensive efforts (surveys, phone calls, CTG abstraction, publication searches), accurate accrual data remained inaccessible for 60% of the RCC trial cohort. While CTG reports trial results, ongoing accrual data are also critically needed. Poor access to accrual data will continue to limit attempts to develop a national summary of clinical trials metrics and to optimize the cancer clinical research portfolio. [Table: see text]
CORONARY INFLAMMATION ASSESSED BY PERICORONARY ADIPOSE TISSUE ATTENUATION ON COMPUTED TOMOGRAPHY ANGIOGRAPHY PREDICTS ATRIAL FIBRILLATION RECCURENCE AFTER CRYOBALLOON ABLATION
Authors: Kai Nogami, Tomoyo Sugiyama, Yoshihisa Kanaji, Masahiro Hoshino, Masao Yamaguchi, Masahiro Hada, Yohei Sumino, Toru Misawa, Hidenori Hirano, Hiroki Ueno, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2020)
Abstract 20032: Regional Differences in Patient Characteristics and Outcomes During Uninterrupted Anticoagulation With Dabigatran versus Warfarin in Catheter Ablation of Atrial Fibrillation: The Re-circuit Study
Authors: Stefan H Hohnloser, Hugh Calkins, Stephan Willems, Atul Verma, Richard Schilling, Ken Okumura, Matias Nordaby, Edward P Gerstenfeld
Journal: Circulation (2017)

Background: RE-CIRCUIT was a prospective, randomized, open-label, blinded adjudicated-endpoint, multicenter study in patients scheduled for catheter ablation for paroxysmal or persistent atrial fib...